ライフサイエンスコーパス: nonmelanoma

1 in ICI-receiving patients with melanoma and nonmelanoma.

2 sociated protein 4 (CTLA-4) therapies in any nonmelanoma advanced cancer should be conducted along wi

3 on mutation types found in crucial genes in nonmelanoma and melanoma skin cancers.

4 also the predominant mutation found in human nonmelanoma and melanoma tumor samples in the TP53, CDKN

5 369.6/100,000 patient-years in patients with nonmelanoma cancer regardless of ICI treatment, compared

6 as evaluated in patients with melanoma, with nonmelanoma cancer, and without cancer.

7 The majority of skin cancer is nonmelanoma cancer, either basal cell cancer or squamous

8 Compared with patients with nonmelanoma cancer, patients with melanoma on any ICI ha

9 ts with melanoma compared with patients with nonmelanoma cancer.

10 Nonmelanoma cancers may involve some ss-1 and ss-2 HPV t

11 Precise removal of nonmelanoma cancers with minimum damage to the surroundi

12 h potential utility against a broad array of nonmelanoma cancers.

13 f vemurafenib in BRAF V600 mutation-positive nonmelanoma cancers.

14 a targetable oncogene in some, but not all, nonmelanoma cancers.

15 BRAF V600 mutations occur in various nonmelanoma cancers.

16 Recent evidence in several nonmelanoma cell systems supports the regulation of the

17 Most wt p53 (nonmelanoma) cell lines (11/12, or 92%) showed clear ind

18 s of melanoma tissue containing an excess of nonmelanoma cells.

19 ween incident primary melanoma cases and the nonmelanoma controls, the risk associated with the homoz

20 with the following two different sources of nonmelanoma controls: spouse/friend controls (n = 84) an

21 ge migration inhibitory factor protects from nonmelanoma epidermal tumors by regulating the number of

22 eceiving a class 1 or class 2 test result in nonmelanoma is possible.

23 its nuclear localization when compared with nonmelanoma/KB-3-1 epidermoid carcinoma cells.

24 patterns among melanomas in comparison with nonmelanoma lesions were included.

25 -type (wt) p53 (5/8, or 63%) compared to the nonmelanoma lines (11/48, or 23%).

26 ults are indeed possible in the setting of a nonmelanoma malignancy.

27 shown that certain spectral shifts occur for nonmelanoma/melanoma lesions against normal/benign nevus

28 y of POH to inhibit photocarcinogenesis in a nonmelanoma model of mouse skin carcinogenesis and its a

29 haracteristic (ROC) = 0.879]; melanomas from nonmelanoma pigmented lesions (ROC = 0.823); and melanom

30 fied to have cytopathology consistent with a nonmelanoma primary.

31 The risk of death from nonmelanoma-ralated causes was similar across Breslow th

32 Finally, nonmelanoma-reactive tumor-infiltrating lymphocyte cultu

33 Risk of death from nonmelanoma-related causes was not associated with Bresl

34 ry outcomes were melanoma-related deaths and nonmelanoma-related deaths.

35 s 77%, which is higher than the 14% found in nonmelanoma samples (P < 0.0001).

36 , 43%-73%), prostate (57%; 95% CI, 51%-63%), nonmelanoma skin (43%; 95% CI, 26%-59%), ovary (39%; 95%

37 The most common malignant neoplasms were nonmelanoma skin (n = 35), breast (n = 24), prostate (n

38 than heterosexual women to report having had nonmelanoma skin cancer (2001-2005 CHIS: aOR, 0.56; 95%

39 most cancer sites, with large increases from nonmelanoma skin cancer (23.4, 21.5-25.5), NHL (5.17, 4.

40 AIH was also linked to nonmelanoma skin cancer (hazard ratio (HR) = 2.69) and l

41 rved being central nervous system (n = 344), nonmelanoma skin cancer (n = 278), digestive (n = 105),

42 mon type of previous cancer in the donor was nonmelanoma skin cancer (n=776) followed by central nerv

43 le of mitochondrial DNA (mtDNA) deletions in nonmelanoma skin cancer (NMSC) and in cutaneous photoagi

44 erum 25-hydroxyvitamin D levels with risk of nonmelanoma skin cancer (NMSC) and melanoma, we evaluate

45 the United States, Europe, and Australia for nonmelanoma skin cancer (NMSC) and melanoma.

46 Protective effects of UV-B radiation against nonmelanoma skin cancer (NMSC) are exerted via signaling

47 ndependently reviewed the DSCMs for residual nonmelanoma skin cancer (NMSC) before and after a brief

48 are suspected to promote the development of nonmelanoma skin cancer (NMSC) by destabilizing the host

49 on-exposed survivors who developed an SN1 of nonmelanoma skin cancer (NMSC) had a cumulative incidenc

50 Nonmelanoma skin cancer (NMSC) has become the most commo

51 accurate measurement of the US incidence of nonmelanoma skin cancer (NMSC) has been difficult.

52 aimed to determine the risk of melanoma and nonmelanoma skin cancer (NMSC) in patients with IBD and

53 was to assess trends in mortality rates for nonmelanoma skin cancer (NMSC) in the United States.

54 osure or other factors, and the incidence of nonmelanoma skin cancer (NMSC) is poorly understood.

55 Nonmelanoma skin cancer (NMSC) is the most common cancer

56 Nonmelanoma skin cancer (NMSC) occurs in photoexposed ar

57 Patients with a periocular region nonmelanoma skin cancer (NMSC) or a nonperiocular NMSC c

58 ot have a greater than expected incidence of nonmelanoma skin cancer (NMSC) or other cancers, whereas

59 Nonmelanoma skin cancer (NMSC) such as cutaneous squamou

60 th 95% CIs for any incident cancer excluding nonmelanoma skin cancer (NMSC) were 1.06 (95% CI, 1.02-1

61 e highly effective in preventing UVB-induced nonmelanoma skin cancer (NMSC) without displaying any ov

62 nd squamous cell carcinoma (typically called nonmelanoma skin cancer (NMSC)).

63 e intake and risks of skin cancer (overall), nonmelanoma skin cancer (NMSC), and basal cell carcinoma

64 d higher risk than HIV-uninfected persons of nonmelanoma skin cancer (NMSC), defined as basal cell ca

65 Various treatment options exist for nonmelanoma skin cancer (NMSC), including topical agents

66 During Mohs micrographic surgery of nonmelanoma skin cancer (NMSC), inflammation in histolog

67 duced immunosuppression is a risk factor for nonmelanoma skin cancer (NMSC), particularly squamous ce

68 ng Medicare billing codes and categorized as nonmelanoma skin cancer (NMSC), viral-linked and "other"

69 in a single patient were counted, except for nonmelanoma skin cancer (NMSC), where only the first was

70 een used as sampling frames for ascertaining nonmelanoma skin cancer (NMSC).

71 player in the development and progression of nonmelanoma skin cancer (NMSC).

72 a and certain noncutaneous cancers following nonmelanoma skin cancer (NMSC).

73 ging is associated with an increased risk of nonmelanoma skin cancer (NMSC).

74 dergoing Mohs micrographic surgery (MMS) for nonmelanoma skin cancer (NMSC).

75 cies (malignancies), including and excluding nonmelanoma skin cancer (NMSC); all malignancies were ex

76 in a case-control study of 191 patients with nonmelanoma skin cancer (NMSC; 81 SCC and 110 basal cell

77 21; 95% CI, 1.51-6.58; P < .003), and having nonmelanoma skin cancer (OR, 8.32; 95% CI, 2.81-21.13; P

78 ), squamous cell carcinoma of the skin (CD), nonmelanoma skin cancer (UC), kidney (CD), and thyroid c

79 ts an avoidable risk factor for melanoma and nonmelanoma skin cancer - both of which may be lethal.

80 ctrum strikingly similar to that reported in nonmelanoma skin cancer and characteristic of DNA damage

81 l carcinoma (cSCC) is the second most common nonmelanoma skin cancer and commonly affects the head an

82 Diagnosis of melanoma or nonmelanoma skin cancer and frequent excisions for benig

83 present in sunlight is the primary cause of nonmelanoma skin cancer and has been implicated in the d

84 pants received a cancer diagnosis, excluding nonmelanoma skin cancer and in situ neoplasms.

85 Nonmelanoma skin cancer and its treatment represent a si

86 ntial and increasing risk for SNs, including nonmelanoma skin cancer and meningiomas.

87 Increases in nonmelanoma skin cancer and nonprogressive, reversible r

88 aviolet A dramatically increases the risk of nonmelanoma skin cancer and prior exposure to psoralen+u

89 reast cancer is the most common cancer after nonmelanoma skin cancer and the second leading cause of

90 vation was clear for all main cancers except nonmelanoma skin cancer and was stronger for cancers of

91 An estimated 5.4 million cases of nonmelanoma skin cancer are reported in the United State

92 s that beta-HPV infections may contribute to nonmelanoma skin cancer by increasing the likelihood tha

93 It is clear that melanoma and nonmelanoma skin cancer control programs combining prima

94 a causative role in ODC up-regulation during nonmelanoma skin cancer development by binding to and st

95 5 cells) to explore the regulation of ODC in nonmelanoma skin cancer development.

96 There were two reported cases of nonmelanoma skin cancer during the follow up of the tran

97 the detection of positive section margins in nonmelanoma skin cancer from 8.4% to 12.8%.

98 the detection of positive section margins in nonmelanoma skin cancer from 8.4% to 12.8%.

99 The incidence of both melanoma and nonmelanoma skin cancer has been increasing over the pas

100 riant was also significantly associated with nonmelanoma skin cancer in a U.K. population.

101 ated with a dose-dependent increased risk of nonmelanoma skin cancer in patients treated for psoriasi

102 play an important part in the development of nonmelanoma skin cancer in psoralen + ultraviolet A-trea

103 nefits and harms of interventions to prevent nonmelanoma skin cancer in solid organ transplant recipi

104 age/repair and prevention of photodamage and nonmelanoma skin cancer in vitiligo.

105 same cumulative dose, which may explain why nonmelanoma skin cancer incidence depends more strongly

106 Nonmelanoma skin cancer is the most common cancer in the

107 While a high risk of nonmelanoma skin cancer is well recognized in solid-orga

108 Across all three trials, adjudicated nonmelanoma skin cancer occurred in five patients who re

109 squamous cell carcinoma (SCC) (often termed nonmelanoma skin cancer or keratinocyte carcinoma [KC])

110 Nonmelanoma skin cancer such as cutaneous squamous cell

111 identified Zmiz1 as a candidate oncogene in nonmelanoma skin cancer through a transposon mutagenesis

112 ium SCT) is a novel noninvasive radionuclide nonmelanoma skin cancer treatment, which can be provided

113 sented ideas can easily be extended to other nonmelanoma skin cancer trials.

114 ative incidence of SMNs was 9.3% and that of nonmelanoma skin cancer was 6.9%.

115 A trend toward decreased risk of nonmelanoma skin cancer was found in those harboring a g

116 the 10 most common cancers in the US and of nonmelanoma skin cancer was not increased with TNFalpha

117 Nonmelanoma skin cancer was not observed among irradiate

118 An excess risk of nonmelanoma skin cancer was observed subsequent to both

119 n, 66 cases of meningioma and 1,007 cases of nonmelanoma skin cancer were diagnosed.

120 with a personal history of cancer other than nonmelanoma skin cancer were excluded.

121 Effects on nonmelanoma skin cancer were uncertain for photodynamic

122 Importance: Keratinocyte carcinoma (nonmelanoma skin cancer) accounts for substantial burden

123 low-up, previous cancer diagnosis (excluding nonmelanoma skin cancer) at enrollment, missing enrollme

124 ohort who had no cancer diagnosis (excluding nonmelanoma skin cancer) at the start of follow-up and r

125 d who had no prior history of cancer (except nonmelanoma skin cancer) were followed prospectively for

126 ORRs were 69% (nonmelanoma skin cancer), 31% (NSCLC), 16% (HCC), and 11

127 of breast cancer or other cancers (excluding nonmelanoma skin cancer), and we completed a personal ba

128 1273 men had any malignant neoplasm (except nonmelanoma skin cancer), as compared with 1293 in the p

129 IN OUTCOME MEASURES: Total cancer (excluding nonmelanoma skin cancer), with prostate, colorectal, and

130 mary cause of skin cancer (both melanoma and nonmelanoma skin cancer).

131 most common cancer type among men (excluding nonmelanoma skin cancer).

132 they had a previous cancer diagnosis (except nonmelanoma skin cancer).

133 and 98 patients developed cancer (excluding nonmelanoma skin cancer).

134 Incident cancer, excluding nonmelanoma skin cancer, after at least 90 days and with

135 nt, severity of AK (Olsen grade), history of nonmelanoma skin cancer, and additional treatment.

136 r TMB and older age at diagnosis, history of nonmelanoma skin cancer, and head and neck tumors relati

137 -degree family history of melanoma, previous nonmelanoma skin cancer, and lifetime sunbed use.

138 feature of diseases like psoriasis, eczema, nonmelanoma skin cancer, and melanoma where differentiat

139 ve an increased incidence of viral warts and nonmelanoma skin cancer, and the presence of HPV DNA in

140 UVR is the major cause of nonmelanoma skin cancer, but other risk factors, includi

141 Prespecified outcomes were nonmelanoma skin cancer, clearance and prevention of ker

142 ity of Pennsylvania, who were diagnosed with nonmelanoma skin cancer, dermatophytosis, acne rosacea,

143 ng, had no prior cancer diagnosis other than nonmelanoma skin cancer, had no prior cancer genetic cou

144 y, we recruited 647 patients with carcinoma, nonmelanoma skin cancer, hematological second cancer, an

145 Nonmelanoma skin cancer, Kaposi sarcoma, and posttranspl

146 ent SMNs were thyroid cancer, breast cancer, nonmelanoma skin cancer, non-Hodgkin's lymphoma, and acu

147 et A is associated with an increased risk of nonmelanoma skin cancer, particularly squamous cell carc

148 aft-versus-host disease as a risk factor for nonmelanoma skin cancer, particularly squamous cell carc

149 a US population-based case-control study of nonmelanoma skin cancer, randomly selected from drivers'

150 that can reduce mortality from melanoma and nonmelanoma skin cancer, screening holds the greatest pr

151 found moderately increased SIR estimates for nonmelanoma skin cancer, smoking-related cancers, and Ho

152 e exposure to sunlight increases the risk of nonmelanoma skin cancer, the avoidance of all direct sun

153 iolet (UV) irradiation is the major cause of nonmelanoma skin cancer, the most common form of cancer

154 were adjusted based on age, sex, history of nonmelanoma skin cancer, US geographic region, and popul

155 tocols and disability, dermatitis, melanoma, nonmelanoma skin cancer, viral skin diseases, and fungal

156 role of the Fragile Histidine Triad gene in nonmelanoma skin cancer, we have used reverse transcript

157 a (MCC) is a highly malignant neuroendocrine nonmelanoma skin cancer, which is associated with the Me

158 ell carcinomas (MCCs), an aggressive form of nonmelanoma skin cancer.

159 anding the pathogenesis of wound healing and nonmelanoma skin cancer.

160 aging nor a higher incidence for sun-induced nonmelanoma skin cancer.

161 se may offer a viable therapeutic option for nonmelanoma skin cancer.

162 nscreen use to prevent actinic keratoses and nonmelanoma skin cancer.

163 adiation in sunlight is the primary cause of nonmelanoma skin cancer.

164 t ranged from 48.7% for myeloma to 31.4% for nonmelanoma skin cancer.

165 llowing UV irradiation, the primary cause of nonmelanoma skin cancer.

166 the major risk factor for the development of nonmelanoma skin cancer.

167 c has been associated with increased risk of nonmelanoma skin cancer.

168 psoriasis patients are at increased risk for nonmelanoma skin cancer.

169 on plays a critical role in the induction of nonmelanoma skin cancer.

170 ng its potential as a therapeutic target for nonmelanoma skin cancer.

171 Mohs surgery for nonmelanoma skin cancer.

172 umor growth in solar-simulated light-induced nonmelanoma skin cancer.

173 a markedly reduced incidence of melanoma and nonmelanoma skin cancer.

174 outcome was total invasive cancer, excluding nonmelanoma skin cancer.

175 global increase in incidence of melanoma and nonmelanoma skin cancer.

176 electrodesiccation and curettage in treating nonmelanoma skin cancer.

177 emal UVR and incident cancer risk, excluding nonmelanoma skin cancer.

178 ith no previous history of cancer other than nonmelanoma skin cancer.

179 global increase in incidence of melanoma and nonmelanoma skin cancer.

180 sion, which contribute to the development of nonmelanoma skin cancer.

181 %]), attributable to the higher incidence of nonmelanoma skin cancer.

182 organ transplants have an increased risk for nonmelanoma skin cancer.

183 quitous in skin and has been associated with nonmelanoma skin cancer.

184 porine have an increased risk for developing nonmelanoma skin cancer.

185 bronchus, and lung; malignant skin melanoma; nonmelanoma skin cancer; breast; cervical; uterine; ovar

186 The primary end point was the number of new nonmelanoma skin cancers (i.e., basal-cell carcinomas pl

187 Excluding nonmelanoma skin cancers (n = 19) and carcinoma-in-situ

188 Nonmelanoma skin cancers (NMSC) are among the most commo

189 V) have been suspected to be carcinogenic in nonmelanoma skin cancers (NMSC), but the basis for poten

190 Cancer registries usually exclude nonmelanoma skin cancers (NMSC), despite the large popul

191 Nonmelanoma skin cancers (NMSCs) are primarily diagnosed

192 Nonmelanoma skin cancers (NMSCs) are the most common can

193 Nonmelanoma skin cancers (NMSCs) in ruxolitinib-treated

194 ous basal cell and squamous cell carcinomas (nonmelanoma skin cancers (NMSCs)), data are insufficient

195 ght to be involved in the initiation of some nonmelanoma skin cancers (NMSCs), particularly in patien

196 des further evidence that for primary facial nonmelanoma skin cancers (NMSCs), recurrence rates with

197 neoplasms, increases the risk of developing nonmelanoma skin cancers (NMSCs).

198 with briakinumab vs. placebo, respectively), nonmelanoma skin cancers (NMSCs; four vs. zero squamous

199 Incidence of melanoma, nonmelanoma skin cancers (squamous cell carcinoma and ba

200 and safety of specific treatments to prevent nonmelanoma skin cancers among solid organ transplant re

201 e and effective in reducing the rates of new nonmelanoma skin cancers and actinic keratoses in high-r

202 Two nonmelanoma skin cancers and two major adverse cardiovas

203 Nonmelanoma skin cancers are among the most common human

204 More than a million cases of nonmelanoma skin cancers are diagnosed every year.

205 ecent dramatic increases in the incidence of nonmelanoma skin cancers are largely attributable to hig

206 Nonmelanoma skin cancers are primarily caused by solar U

207 UV radiation may lead to melanoma and nonmelanoma skin cancers by causing helix-distorting DNA

208 eningiomas, and 1.71 (95% CI, 0.88-3.33) for nonmelanoma skin cancers for survivors with reference ch

209 ll effect of screening for both melanoma and nonmelanoma skin cancers has not been achieved.

210 12-month intervention period, the number of nonmelanoma skin cancers in the 6-month postintervention

211 o, 386 participants who had had at least two nonmelanoma skin cancers in the previous 5 years to rece

212 e finding of TRPV4 downregulation in several nonmelanoma skin cancers into context.

213 The elevated risks of nonmelanoma skin cancers might indicate an association w

214 Nonmelanoma skin cancers occur primarily in individuals

215 hree patients who underwent Mohs surgery for nonmelanoma skin cancers presented between 2 and 4 weeks

216 Nonmelanoma skin cancers that required at least 3 Mohs m

217 At 12 months, the rate of new nonmelanoma skin cancers was lower by 23% (95% confidenc

218 .44-4.27) with placebo/dexamethasone; IRs of nonmelanoma skin cancers were 2.40 (95% CI, 1.33-4.33) a

219 SMNs), and relative risks (RRs) for SMNs and nonmelanoma skin cancers were calculated.

220 Second primary malignancies excluding nonmelanoma skin cancers were seen in 5.5% and myeloid m

221 renal papillary, and rectal cancer and three nonmelanoma skin cancers) among 825 patients who receive

222 Combined cancer incidence (excluding nonmelanoma skin cancers) from 1987 to 2006 was captured

223 the incidence of all-type cancer (excluding nonmelanoma skin cancers), which was evaluated using Kap

224 rt members, 730 reported 802 SMNs (excluding nonmelanoma skin cancers).

225 These included 196 SMNs, 419 nonmelanoma skin cancers, 21 nonmalignant meningiomas, a

226 Excluding nonmelanoma skin cancers, 55 second cancers were seen in

227 rs, six non-MDS hematologic malignancies, 39 nonmelanoma skin cancers, and 68 cases of MDS/acute myel

228 Administration approved for the treatment of nonmelanoma skin cancers, but it has limited activity ag

229 Nonmelanoma skin cancers, in particular cutaneous squamo

230 lomaviruses (HPVs) have been associated with nonmelanoma skin cancers, particularly in immunocompromi

231 an papilloma virus infections and associated nonmelanoma skin cancers, providing additional genetic a

232 Nonmelanoma skin cancers, such as basal-cell carcinoma a

233 ccurring > 5 years from diagnosis, excluding nonmelanoma skin cancers, were evaluated in survivors di

234 human cancers, including melanoma and other nonmelanoma skin cancers.

235 ent of precancerous skin lesions and certain nonmelanoma skin cancers.

236 the most prevalent mutations found in human nonmelanoma skin cancers.

237 n phenotypes and development of melanoma and nonmelanoma skin cancers.

238 ic receptors as a new treatment modality for nonmelanoma skin cancers.

239 multiple tumor types, including melanoma and nonmelanoma skin cancers.

240 lignancies, 233 benign meningiomas, and 1856 nonmelanoma skin cancers.

241 vents keratinocyte carcinomas, also known as nonmelanoma skin cancers.

242 or subsequent malignancies, meningiomas, and nonmelanoma skin cancers.

243 a-HPVs) may contribute to the development of nonmelanoma skin cancers.

244 a or skin squamous cell carcinoma or cSCC or nonmelanoma skin neoplasms." Study Selection: Articles w

245 Animals were monitored for the appearance of nonmelanoma skin tumors (NMSTs) and melanocytic hyperpla

246 with accelerated and increased formation of nonmelanoma skin tumors during chemical carcinogenesis.

247 The incidence of malignancy (excluding nonmelanoma skin tumors) was determined in these 1886 pa

248 s are frequently observed in the p53 gene of nonmelanoma skin tumors.

249 ould efficiently recognize NY-ESO-1-positive nonmelanoma tumor cell lines.

250 c reactivity against a range of melanoma and nonmelanoma tumor cells.

251 but not HLA-mismatched melanoma or gp100(-) nonmelanoma tumor lines.

252 monstration of the successful treatment of a nonmelanoma tumor using TCR-transduced T cells.

253 Similar efforts for nonmelanoma tumors have had limited success with few ant

254 genesis, instead inducing the development of nonmelanoma tumors that included squamous cell carcinoma

255 a distinct syngeneic melanoma, but not with nonmelanoma tumors.

256 relating features of pigmented NM vs nodular nonmelanoma were peripheral black dots/globules, multipl